Business Context and Reporting Period
Company: MannKind Corporation (MannKind)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: MannKind is a development-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Its lead product candidate is the Technosphere Insulin System, a proprietary dry powder insulin formulation delivered via inhalation, currently in Phase 3 clinical trials. The company has no commercial products and has not generated product revenue since its inception in 1991.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2005 | Nine Months Ended Sept 30, 2005 | Cumulative from Inception to Sept 30, 2005 |
|---|---|---|---|
| Revenue | $0 | $0 | $2,858 |
| Net Loss | $(31,730) | $(81,047) | $(524,010) |
| Net Loss per Share (Basic & Diluted) | $(0.73) | $(2.23) | N/A |
| Cash and Cash Equivalents | $69,238 | N/A | N/A |
| Marketable Securities | $113,166 | N/A | N/A |
| Total Current Assets | $187,106 | N/A | N/A |
| Total Current Liabilities | $18,960 | N/A | N/A |
| Accumulated Deficit | $(524,010) | N/A | $(524,010) |
Cash Flow (Nine Months Ended Sept 30, 2005):
- Operating Activities: Net cash used of $70.8 million.
- Investing Activities: Net cash used of $111.3 million (primarily purchases of marketable securities and property/equipment).
- Financing Activities: Net cash provided of $172.3 million (primarily from a private placement).
Material Changes vs. Prior Period
- Revenue: No product revenue was recorded for the three or nine months ended September 30, 2005, consistent with the prior year periods.
- Operating Expenses:
- Research & Development (R&D): Increased 108% to $24.5 million for the quarter (from $11.8 million in 2004) and 72% to $66.8 million for the nine-month period (from $38.9 million in 2004). Increases were driven by clinical trial costs for the Technosphere Insulin System, manufacturing expansion, and research into cancer therapies.
- General & Administrative (G&A): Decreased slightly to $8.4 million for the quarter (from $8.7 million in 2004) and remained flat at $16.3 million for the nine-month period. This was due to a significant decrease in stock-based compensation expense offset by higher salaries and professional fees.
- Stock-Based Compensation: Decreased significantly due to the decline in the company's stock price since December 31, 2004, which reduced the valuation of repriced stock options.
- Liquidity: Cash and marketable securities increased substantially following a private placement in August 2005. Total liquid assets (cash, cash equivalents, and marketable securities) stood at approximately $182.4 million as of September 30, 2005.
Guidance, Outlook, Risks, and Unusual Items
Capital Resources and Outlook:
- The company completed a private placement on August 5, 2005, raising net proceeds of approximately $170.2 million.
- Management believes existing capital resources will fund planned operations into the third quarter of 2006.
- Future funding will be required for continued clinical trials, manufacturing expansion, and commercialization efforts. If additional capital is not raised, the company may need to reduce or delay development activities.
Unusual Items:
- Goodwill Impairment: The cumulative net loss includes a one-time goodwill impairment charge of $151.4 million recognized in prior periods (specifically 2004).
- State R&D Credits: The company recognized $1.1 million in research and development tax credit exchange receivables for the nine months ended September 30, 2005, partially offsetting R&D expenses.
Risks and Contingencies:
- Regulatory Approval: Success depends on FDA approval of the Technosphere Insulin System, which is a combination product (drug and device) requiring review by multiple FDA divisions. No assurance of approval exists.
- Competition: Competitors such as Pfizer/sanofi-aventis (Exubera) and Eli Lilly/Alkermes are developing inhaled insulin products. Exubera received positive opinions from FDA and European advisory committees in late 2005.
- Legal Proceedings:
- Former CMO Litigation: Dr. Wayman Cheatham, former Chief Medical Officer, sued the company for wrongful termination, breach of contract, and retaliation, seeking over $2.0 million. The company filed a cross-complaint for libel and breach of contract. Trial is scheduled for July 2006.
- Notes Receivable: The company is pursuing collection on notes receivable totaling approximately $14.6 million due from consultants, which were exchanged for stock in 2000. The company does not currently deem these uncollectible.
- Manufacturing: The company has never manufactured products in commercial quantities and faces risks in scaling up production and passing FDA pre-approval inspections.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the $170.2 million net proceeds from the August 2005 private placement and the projected burn rate to confirm the "third quarter of 2006" liquidity timeline.
- Clinical Trial Status: Confirm the current status and enrollment numbers of the Phase 3 clinical trials for the Technosphere Insulin System, as these are the primary drivers of R&D expenses.
- Legal Exposure: Monitor the progress of the litigation with Dr. Cheatham and the collection efforts regarding the $14.6 million in notes receivable to assess potential financial impact.
- Competitive Landscape: Track the regulatory approval status of competitor inhaled insulin products (specifically Exubera) which could impact MannKind's market opportunity.
- Stock-Based Compensation: Review the impact of the upcoming adoption of SFAS No. 123R (effective Jan 1, 2006) on future reported net losses, as the company currently uses the intrinsic value method.